Tounjian Advisory Partners’s Globus Medical GMED Stock Holding History

Tounjian Advisory Partners’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$790	Buy	+10	New	+$850	﹤0.01%	683

Other funds holding GMED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.36B AUM 17.81% 1-Year Est. Return

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ACA

Anchor Capital Advisors Boston, Massachusetts $3.56B AUM 21.74% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Tounjian Advisory Partners's GMED Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Globus Medical (GMED) in Q2 2026: 10 shares worth $790. The stake represents ﹤0.01% of the portfolio and ranks #683 among its holdings.

320 funds tracked by Wall St. Rank hold GMED as of Q2 2026.

Tounjian Advisory Partners held 10 shares of Globus Medical worth $790 as of Q2 2026.
Globus Medical was a new Tounjian Advisory Partners position in Q2 2026.
Globus Medical made up ﹤0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #683 holding.
320 funds tracked by Wall St. Rank held Globus Medical as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.